Caterina Anecchino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caterina Anecchino has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Gianni Tognoni
2 shared publications- Antonio Nicolucci
Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
1 shared publication Arianna Masciulli
1 shared publicationCaterina Fanizza
Pharmacoepidemiology laboratory, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
1 shared publicationDaniela D'alonzo
1 shared publicationElisa Rossi
CINECA Interuniversity Consortium, Bologna, Italy “ARNO project” working group: M Andretta (VR), L Castellani (Bussolengo), M Cecchetto (Bassano), M De Cal (BL), R Di Turi (RM-D), R Gallo (VI), D Garibaldi (LU), AM Grion (PD),M Grossetti (GE), G La Bella (NA-1), F Lena (LI), D Maccari (Pieve di Soligo), C Marinai (FI), M Moruzzo (SP), E Nava (NA-4), A Orsini (TE), B Pari (Chioggia), A Pedrini (Alta padovana), M Rais (Viareggio), G Rizzotti (Adria), MP Cariolato (Ovest Vicentino), MG Zogno (Este)
1 shared publication
Latest Publications
- 3 June 2010
- Vol. 29 (1) , 26-40
[Memorandum for the management of clinical trials].
A critical appraisal of the recent legislation on clinical trials is proposed, together with some reflections on the implications on the practice and principles of clinical experimentation. The possible role and contribution of Ethical Committees is discussed.
- 3 June 2010
- Vol. 29 (1) , 26-40
[Memorandum for the management of clinical trials].
A critical appraisal of the recent legislation on clinical trials is proposed, together with some reflections on the implications on the practice and principles of clinical experimentation. The possible role and contribution of Ethical Committees is discussed.
- 1 December 2007
- Vol. 2 (4) , 567-574
Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population
Nowadays, there is increasing awareness about the frequent chronic comorbidities in patients with chronic obstructive pulmonary disease (COPD) but little information is available to quantify the burden of illness that these conditions cause in this population. We aimed to identify and describe a population suffering from COPD highlighting the co-morbid conditions that may contribute to poor clinical outcomes. Epidemiological cross-sectional study conducted using administrative heath services databases. A cohort of 126,283 COPD patients was identified. The estimated prevalence in adult population was 3.6%. Ninety-eight percent of these patients (123,603) received at least one prescription of “non-respiratory drugs” and, considering chronic specific comorbidities (cardiovascular disease, diabetes and depression) 86,351 patients (68.4% of COPD patients) suffered from at least one of these conditions. 80,840 pts (64.4%) were treated for cardiovascular diseases, 17,091 subjects for diabetes (12.4%) and 10,292 for depression (8%). About 16% of COPD subjects (19,168 patients) had two out of the three considered comorbid conditions and 1352 patients (1.1%) all three. This study highlights the complex spectrum of comorbidities in COPD patients. The prevalence of main chronic diseases increases with age, in particular among female group. An enhanced public awareness about these conditions is necessary, just as a more comprehensive approach in their management.
- 1 December 2007
- Vol. 2 (4) , 567-574
Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population
Nowadays, there is increasing awareness about the frequent chronic comorbidities in patients with chronic obstructive pulmonary disease (COPD) but little information is available to quantify the burden of illness that these conditions cause in this population. We aimed to identify and describe a population suffering from COPD highlighting the co-morbid conditions that may contribute to poor clinical outcomes. Epidemiological cross-sectional study conducted using administrative heath services databases. A cohort of 126,283 COPD patients was identified. The estimated prevalence in adult population was 3.6%. Ninety-eight percent of these patients (123,603) received at least one prescription of “non-respiratory drugs” and, considering chronic specific comorbidities (cardiovascular disease, diabetes and depression) 86,351 patients (68.4% of COPD patients) suffered from at least one of these conditions. 80,840 pts (64.4%) were treated for cardiovascular diseases, 17,091 subjects for diabetes (12.4%) and 10,292 for depression (8%). About 16% of COPD subjects (19,168 patients) had two out of the three considered comorbid conditions and 1352 patients (1.1%) all three. This study highlights the complex spectrum of comorbidities in COPD patients. The prevalence of main chronic diseases increases with age, in particular among female group. An enhanced public awareness about these conditions is necessary, just as a more comprehensive approach in their management.